Anti-LARP7 antibody

• IP

Unknown

Immunoprecipitation - Anti-LARP7 antibody (AB134746)

Detection of LARP7 by Western Blot of Immunprecipitate.
Immunoprecipitation analysis of HeLa whole cell lysate (1 mg for IP, 20% of IP loaded), using ab134746 at 6 µg/mg lysate for IP.
Detection : Chemiluminescence with exposure time of 10 seconds.

All lanes:

Immunoprecipitation - Anti-LARP7 antibody (ab134746)

Predicted band size: 66 kDa

false

• WB

Unknown

Western blot - Anti-LARP7 antibody (AB134746)

Western Blot Gel 4-20%

All lanes:

Western blot - Anti-LARP7 antibody (ab134746) at 0.1 µg/mL

Lane 1:

HeLa whole cell lysate at 50 µg

Lane 2:

HeLa whole cell lysate at 15 µg

Lane 3:

293T whole cell lysate at 50 µg

Lane 4:

Jurkat whole cell lysate at 50 µg

Lane 5:

NIH 3T3 whole cell lysate at 50 µg

Predicted band size: 66 kDa

true

Exposure time: 10s

• WB

CiteAb

Western blot - Anti-LARP7 antibody (AB134746)

LARP7 western blot using anti-LARP7 antibody ab134746. Publication image and figure legend from Bywater, M. J., Burkhart, D. L., et al., 2020, Nat Commun, PubMed 32286286.

ab134746 was used in this publication in western blot. This may not be the same as the application(s) guaranteed by Abcam. For a full list of applications guaranteed by Abcam for ab134746 please see the product overview.

Inhibition or overexpression of P-TEFb modulates efficiency of Myc-driven transcription.a Immunoblot analysis of the C-terminal domain (CTD) of RNA Polymerase II—total (Rpb1) and phosphorylated (p-Rpb1(S5) and p-Rpb1(S2)), CDK9, Cyclin T1 and Larp7 expression in the heart, liver, lung and kidney isolated from wild-type (R26+/+) mice. The composite figure is generated from the same samples loaded across multiple blots and a representative image for GAPDH is shown. b Immunoblot analysis of the CTD of RNA Polymerase II, phosphorylated (p-Rpb1(S2)), and MycERT2 protein expression in wild type (R26+/+) or R26CMER/+ livers, isolated 4 h post administration of 4-OHT either alone (4-OHT) or in combination with 60 mg/kg AZ5576 (4-OHT + AZ5576). c Quantitative RT-PCR analysis of Smpdl3b, Cad, Gnl3 and Polr3g in wild type (R26+/+) and R26CMER/+ livers, isolated 4 h post administration of 4-OHT (n = 6 R26+/+, n = 3 R26CMER/+) either alone or in combination with 60 mg/kg AZ5576 (4-OHT + AZ5576, n = 4). Expression is relative to the respective wild type (R26+/+). Mean and s.d shown. Two-way ANOVA with Tukey’s multiple comparisons test; R26+/+ vs 4-OHT : ***P = 0.001 (Smpdl3b,Cad,Gnl3 and Polr3g), R26CMER/+ 4-OHT vs 4-OHT + AZ5576 : ***P = 0.001 (Smpdl3b, Cad and Gnl3), **P ≤ 0.01 (Polr3g). d Immunoblot analysis of Cyclin T1 and phosphorylated CTD of RNA polymerase II (p-Rpb1(S2)) in R26CMER/+ primary cardiomyocytes infected with an adenovirus encoding either GFP (Ad-GFP) or Ccnt1 (Ad-Ccnt1). Replicate samples are derived from independent primary cardiomyocyte isolations. e Quantitative RT-PCR analysis of Cad, Bzw2, Pinx1, Polr3d, St6 and Cdc25a in wild type (R26+/+, n = 5 except Pinx1 where n = 4 for Ad-GFP control) and R26CMER/+ (n = 5 except St6 where n = 4 for Ad-GFP control) primary cardiomyocytes infected with an adenovirus encoding either GFP (Ad-GFP) or Ccnt1 (Ad-Ccnt1), 4 h post addition of 100 nM 4-OHT. Expression is relative to an individual wild type (R26+/+) Ad-GFP control. Mean and s.d shown. One-way ANOVA with Tukey’s multiple comparisons test; Ad-GFP R26+/+ vs R26CMER/+ : *P = 0.05 (Cad), Ad-Ccnt1R26+/+ vs R26CMER/+ : *P = 0.05 (Cad, Pinx1, Polr3d and St6) **P = 0.01 (Bzw2 and Cdc25a). Replicate samples are derived from independent primary cardiomyocyte isolations and independent mice. Source data are provided as a Source Data file.

false